• Akebia Therapeutics swung to a third-quarter 2026 net loss of $14.4 million from year-earlier net income of $0.5 million.
• Total revenues fell 37% year-over-year to $36.9 million due to lower Auryxia revenues.
• Auryxia net product revenues dropped 53% year-over-year to $20 million, while Vafseo's rose to $14.8 million.
• Patients receiving Vafseo more than doubled from a year earlier to approximately 11,500 at quarter-end.
• The VOCAL trial met its primary endpoint, demonstrating vadadustat's non-inferiority to erythropoiesis-stimulating agents in maintaining hemoglobin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050710PRIMZONEFULLFEED9870836) on November 05, 2026, and is solely responsible for the information contained therein.